New research indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop traditional lifestyle plans.
Research printed in a prominent medical journal demonstrates that while overweight individuals can lose substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these treatments must be aware of the risk of fast weight regain when the treatment ends," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original mass in about 18 months.
Weighing Treatments
The study, which examined dozens of trials involving thousands of participants, contrasted the results of these new drugs with older methods.
The team emphasize that people who lose weight through diet and exercise usually see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Experts suggest the mode of action of the drugs explains the heightened regain.
The injections copy a natural hormone called GLP-1, which controls appetite.
"Long-term administration of the hormone concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Medical guidelines advise the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, given the high risk of weight regain, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "emphasize the chronic character of obesity," comparing it to managing conditions like high blood pressure.
User Testimonies
Individuals who have stopped the medication explain a intense resurgence of cravings.
"It felt as if a switch that goes on and you become extremely hungry," said an individual.
This challenge is compounded if patients have not adopted permanent lifestyle or habit modifications during therapy.
Significant Interest
Recent estimates suggest that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss hinges on combined behavioural changes.
